Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes-Reference-Cited by-同舟云学术

Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes

Published:2023-04-10 Issue:3 Volume:14 Page:294-297
ISSN:2190-1678
Container-title:Diabetology International
language:en
Short-container-title:Diabetol Int

Author:

Yamada Tomoko,Asahara Shun-ichiro^ORCID,Kimura-Koyanagi Maki,Tamori Yoshikazu,Muramae Naokazu,Mori Kenta,Okano Mitsumasa,Otsui Kazunori,Sakaguchi Kazuhiko

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13340-023-00621-5.pdf

Reference16 articles.

1. Gomez-Peralta F, Al-Ozairi E, Jude EB, Li X, Rosenstock J. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: a novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes Obes Metab. 2021;23:1445–52. https://doi.org/10.1111/dom.14365.

2. Watada H, Takami A, Spranger R, Amano A, Hashimoto Y, Niemoeller E. Efficacy and safety of 1:1 fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide in Japanese patients with Type 2 diabetes inadequately controlled on oral antidiabetic drugs: The LixiLan JP-O1 randomized clinical trial. Diabetes Care. 2020;43:1249–57. https://doi.org/10.2337/dc19-2452.

3. Pei Y, Agner BR, Luo B, Dong X, Li D, Liu J, et al. Dual II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin. Diabetes Obes Metab. 2021;23:2687–96. https://doi.org/10.1111/dom.14522.

4. Kaneto H, Koshida R, Baxter M. Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: an innovative solution to a complex therapeutic challenge. Diabetes Obes Metab. 2020;22(Suppl 4):24–34. https://doi.org/10.1111/dom.14095.

5. McCrimmon RJ, Cheng AYY, Galstyan G, Djaballah K, Li X, Coudert M, et al. iGlarLixi versus basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: the SoliSimplify Real-World study. Diabetes Obes Metab. 2022. https://doi.org/10.1111/dom.14844.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2023-08-26